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SulTllTlary 
The influence of costimulation on the primary response of CD8 + T  cells to class I alloantigens 
was studied with the aid of a T  cell receptor transgenic model and defined peptides as antigen. 
With small doses of antigen, the proliferative response of CD8 + cells was high early in culture 
but was of brief duration and declined to low levels by day 4; this abbreviated response was as- 
sociated with limited production ofinterleukin 2 (IL-2) and was strongly dependent upon co- 
stimulation via CD8-major histocompatibility complex class I and CD28-B7 interactions. The 
response to large doses of antigen was quite different in two respects. First, large doses of anti- 
gen inhibited the early (day 3) proliferative response but caused a marked elevation of the re- 
sponse late in culture (day 5); these altered kinetics were associated with increased production 
of IL-2. Second, the initial proliferative response to large doses of antigen did not require co- 
stimulation: indeed, blocking costimulation with CTLA4Ig or anti-CD8 monoclonal antibody 
enhanced  the  early proliferative response.  However,  blocking  costimulation  impaired  IL-2 
production and prevented the late proliferative response. These findings indicate that the re- 
quirement for costimulation ofT cells can be partly overcome by increasing the dose of antigen 
to a high level. However, costimulation plays a key role in prolonging the response, presum- 
ably by triggering strong and sustained production of IL-2. 
F 
~rimary responses ofT cells are directed to peptide frag- 
ments of antigen bound to MHC molecules on APCs 
(1, 2). T  cells recognize peptide-MHC complexes via cx/[3 
TCR molecules in conjunction with CD8 and CD4 corecep- 
tors. By binding to MHC class I and class II molecules, re- 
spectively, CD8 and CD4 coreceptors promote TCR con- 
tact with peptide-MHC  complexes and thereby augment 
the avidity of T-APC  interaction.  CD8  and  CD4  mole- 
cules  also  enhance  signaling  by focusing tyrosine kinases 
such as p56  lck in the vicinity of TCR-CD3 complexes (3). 
In addition to displaying peptide-MHC complexes, APCs 
express a variety of costimulatory molecules  (1-4).  These 
molecules interact with complementary molecules on T ceils 
and deliver "second signals"  for T  cell activation. Particular 
attention has been focused on costimulation delivered via 
CD28-B7 interaction (5, 6). T  cell CD28 molecules bind 
to either B7-1 or B7-2 molecules on APCs and are thought 
to transduce unique signals that stimulate T  cell production 
of growth-promoting cytokines such as IL-2. 
Although  the  notion  that  stimulation  of unprimed  T 
cells requires two qualitatively different signals has achieved 
wide acceptance, it is clear that costimulation is not unique 
to CD28-B7 interaction. Thus, several other molecules on 
APCs, induding intercellular adhesion molecule 1 (ICAM-1) 1 
and heat-stable  antigen (HSA), can exert quite potent cosfirn- 
ulatory function (for review see reference 7). The implica- 
tion therefore is that T-APC interaction is highly complex 
and involves multiple interactions between complementary 
sets of molecules on T  cells and APCs. A priori, each set of 
molecules could induce unique patterns of  signal transduction, 
the  combined  action  of these  different  signals  being  re- 
quired for optimal T cell stimulation. Alternatively, costim- 
ulatory molecules may function largely (or partly) as adhesion 
molecules and act by enhancing the avidity of T-APC in- 
teraction, thereby promoting optimal cross-linking of  TC1L- 
CD3 complexes (8). 
In considering these two possibilities,  it is important to 
know the minimal requirements for stimulating unprimed 
T  cells.  The  literature  on  this  topic  is  confusing,  Thus, 
studies with CD28 knockout mice and blocking B7 func- 
tion with CTLA4Ig indicate that CD28-B7  interaction is 
highly important in some situations  (9)  but not in  others 
1Abbreviations used in this paper: DC, dendritic cell; HSA, heat-stable anti- 
gen; ICAM-1, intercellular  adhesion molecule 1; MFI, mean fluorescence 
intensity; OGDH, 2-oxoglutarate  dehydrogenase;  PI, propidium  iodide. 
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ceptors  in primary responses  is  not  an  invariable finding 
(12,  13). 
The  simplest resolution to  this problem is  that  the  re- 
quirement for costimulation varies according to the affinity 
of TC1k-peptide--MHC interaction: low affinity interactions 
are heavily dependent on signal boosting from coreceptors 
and costimulatory molecules, whereas high affinity interac- 
tions are not. In hne with this idea, we present evidence that 
early primary responses ofCD8 + T  cells to alloclass I-peptide 
complexes are only dependent on costimulation via CD8- 
class I and CD28-B7 interactions when the dose of antigen 
is low.  In fact,  with very strong TCR-peptide-MHC  in- 
teraction, costimulation is inhibitory and causes a marked re- 
duction ofT cell responses. Paradoxically, however, the in- 
hibitory effect of costimulation is transient and is followed 
by marked augmentation of the response later in culture. 
Materials and Methods 
Mice.  2C TCR transgenic  mice, obtained from Dr. D. Loh 
(14), and B10.D2/NSnJ mice were bred and maintained at The 
Scripps Research Institute. 
Cell Line and mAbs.  The  following mAbs were  used:  3.168 
(anti-CD8) (15), RL172 (anti-CD4) (15), J11d (anri-HSA)  (15), 
28-16-8s (anri-I-A  b) (15), FD441.8 (anti-LFA-1) (15), and 30-5-7 
(anti-L  d)  (16). The RMA-S.L  d cell line and the anti-clonotypic 
1B2 mAb were kindly provided by Dr. H. Eisen (Massachusetts In- 
stitute of Technology, Cambridge, M_A) (16, 17). Purified CTLA4Ig 
fusion protein was a gift ofP. Linsley (18). 
Peptides.  Peptides  were provided by Dr. A. Brunmark from 
R.W. Johnson Pharmaceutical Research Institute (La Jolla,  CA) 
and were synthesized on a 431 A synthesizer (Apphed Biosystems, 
Inc., Foster City, CA) and were purified with C18 reverse-phase 
HPLC. The concentrations ofpeptides were determined on the 
basis of their molecular weights. 
Media.  For measuring proliferative responses, RPMI 1640 was 
supplemented with 10% FCS (Irvine Scientific, Santa Ana, CA), 
5% NCTC 109, 2 mM glutamine, 5 ￿  10 -5 M 2-ME, and anti- 
biotics (19). 
Induction  and  Stabilization  of L d Expression  on  RMA-S.L d Cells. 
RMA-S.L  d cells precultured at 25~  overnight were incubated 
with peptides for 8-16 h at 25~  (20). Induction ofL  d expression 
was then measured by staining the cells with anti-L  d mAb fol- 
lowed by a FITC-labeled second Ab (see flow cytometric analy- 
sis). For the stabilization assay, RMA-S.L  d cells preincubated with 
peptides  at 25~  were cultured at 37~  for an additional 6 h and 
then stained for surface L  d expression. The mean fluorescence  in- 
tensity (MFI) of staining was determined by FACS  |  analysis. The 
MFIs ofL  d expression for RMA-S.L  d cells cultured at 37~  and at 
25~  in the absence ofpeptides were 4 and 29, respectively. 
Purification of CD8 + and CD8-  2C Cells.  For cell purification 
(15), 2C LN cells were first treated with a cocktail of mAbs (anti- 
CD4,  anti-HSA, anti-I-A  b) plus complement (C)  for 45 rain at 
37~  The surviving cells were further separated into CD8 + and 
CD8-  (CD4-) cells by panning at 4~  for 60-90 rain on petri 
dishes coated with anti-CD8 mAb. Nonattached cells were eluted 
and treated with anti-CD8 mAb and C to obtain CD8- 1B2 + 2C 
cells. The attached  (CD8 +) 1B2 + 2C cells were recovered by in- 
cubation at 37~  for 5 min followed by vigorous pipetting. 
Proliferation Assay.  Purified populations ofCD8 + or CD8- 2C 
cells were cultured with irradiated stimulator cells in 200-pL1 wells 
(15). RMA-S.L  d stimulators  were cultured overnight at 25~  in 
flasks, exposed  to 3,000  cGy, washed,  incubated at 5 ￿  10  s cells 
per n'fl  with peptides  overnight at 25~  and then, without wash- 
ing,  plated  out  in 200-1-1 wells  with  the  responder  cells. For 
B10.D2 spleen or dendritic cells (DCs), these cells were exposed 
to 2,000  cGy, washed,  incubated at  5  ￿  106  cells per ml with 
peptides  at 25~  for 2 h, and then plated out with the responder 
cells without washing. Unless stated otherwise, responder cells were 
used at 2.5 ￿  104 cells per well; the dose ofsrimulator cells varied 
but was generally 5 ￿  104 cells per well for RMA-S.L  d cells, 5 ￿ 
105 cells per well for spleen cells, and 5-10 X 104 cells per well for 
DCs. DCs were purified according to established methods (19). 
To measure T cell prohferation, cultures were pulsed with 1 I~Ci 
of [3H]thymidine  8 h before harvest.  The data in the tables and 
figures refer to the mean of triplicate cultures; SDs were generally 
within 5-15% of the mean. 
Generation of CTLs and CTL Assays.  By use of 2 ml volumes 
and 24-well plates, 5 ￿  10  s CD8 + 2C cells were cultured for 4 d 
with 5 ￿  10  s RMA-S.L  d cells irradiated with 3,000 cGy and pre- 
treated with peptides; peptides  (p2Ca or QL9) were present dur- 
ing the culture at a concentration of 10 I.tM. To prepare  targets, 
RMA-S.L  d cells were labeled with SlCr (100 ~Ci per 1-2 ￿  106 
cells) at 37~  for 90 min in the presence  or absence of peptides. 
After labeling, the cells were thoroughly washed and resuspended 
in medium with or without peptides.  Specific 51Cr release was 
calculated according to established procedures  (15). 
IL-2 Production.  IL-2 production was measured  by using an 
IL-2-dependent cell line, CTLL (15). At the rimes indicated, 50 t*1 
of culture supernatant was added to 5,000 CTLL cells for 24 h; 
1 IxCi [3H]TdR was added  16 h before harvest.  The data in the 
figures are expressed as the mean of triplicate cultures.  IL-2 activ- 
ity in the supernatants  was not titrated routinely, although ran- 
dom titrarions  of supematants showed a direct  correlation with 
CTLL cpm below 80,000 cpm. Parallel titrations with rlL-2 showed 
that 20--30 U oflL-2/ml were required to reach 80,000 cpm with 
the CTLL line under the conditions used. 
Flow Cytometric Analysis.  For analysis  of surface expression ofL  d 
on RMA-S.L  d cells, 5 ￿  10  s cells were incubated with anti-L  d mAb 
for 30 rain on ice, washed in PBS buffer with 2.5% horse serum 
and 0.1% of sodium azide, and then stained with FITC-conjugated 
goat F(ab)'2 anti-mouse Fc"/antibody (Jackson ImmunoResearch 
Laboratories,  West Grove, PA).  TCR expression  on CD8 + 2C 
cells was measured with FITC-conjugated 1B2 mAb. PE-conju- 
gated anti-CD8 mAb was purchased  from GIBCO BRL (Gaith- 
ersburg,  MD).  Dead  cells were  stained  with propidium iodide 
(PI) (Sigma Chemical Co., St. Louis, MO). Data  on viable cells 
were acquired and analyzed on a FACScan  |  using Lysys software 
(Becton Dickinson, San Jose, CA). 
Results 
Background.  The requirements for stimulating unprimed 
T  cells were examined with the aid of the 2C hne of TCR 
transgenic mice (14).  As discussed below, the unique fea- 
ture of the 2C line is that the TCR  specificity of this line 
and the binding affinities involved in TCP,.-peptide-MHC 
interaction are well defined. 
2C T  cells are MHC class I restricted and undergo posi- 
tive selection in the thymus to  K b molecules (21).  At the 
level of mature T  cells,  CD8 +  2C  cells display strong al- 
loreactivity to  L d and give high primary prohferative  re- 
sponses and CTL activity to L  d (B10.D2) spleen cells in the 
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2C  cells for L a is directed to a  naturally occurring peptide 
termed p2Ca  (16).  This  8-mer peptide is  derived from  a 
Krebs cycle enzyme, 2-oxoglutarate dehydrogenase (OGDH) 
(22); p2Ca has intermediate affinity for L a molecules and, 
when complexed to L a, displays high affinity for cell-bound 
and soluble 2C TCR  molecules (23, 24)  (Table 1). A  9-mer 
variant of p2Ca,  termed QL9,  has  100-fold higher binding 
affinity for L d than p2Ca and 10-fold higher affinity for 2C 
TCR  molecules (25); except for one extra amino acid, QL9 
has the same sequence as p2Ca, and, like p2Ca, QL9 forms 
part of the natural sequence of OGDH. 
For  mature  LN  T  cells, ~98%  of CD8 +  2C  cells are 
clonotype  positive  (1B2+),  and  "~98%  of 1B2 +  cells  are 
CD441~  indicative of a naive phenotype (Fig. 1 a). Expres- 
sion of TCR  or-chain expression by 2C T  cells is presum- 
ably minimal because 1B2 expression on 2C T  cells is uni- 
formly  high  and  homogenous  (Fig.  1  b).  This  applies  to 
both CD8 + and CD8-  (CD413  1B2 +) 2C cells; CD8 + and 
CD8-  subsets of2C T  cells exist as distinct nonoverlapping 
subsets and can be purified by mAb plus C  treatment and 
panning (Fig. 1 b). 
Using purified CD8 +  and CDS-  2C cells and synthetic 
p2Ca and QL9 peptides, we examined the requirements for 
CD8-MHC  and CD28-B7  interaction in the primary re- 
sponse  of 2C  cells.  We  established previously that  these 
interactions are crucial for the response of 2C cells to normal 
B10.D2 spleen as APCs, i.e., where the response is directed to 
L a plus endogenous  p2Ca peptide  (15).  The  question  ad- 
dressed below is whether the requirement for costimulation 
decreases  when  the  avidity  of T-APC  interaction  is  in- 
creased, i.e., when APCs are supplemented with exogenous 
p2Ca  or  QL9  peptide.  We began by using Ld-transfected 
RMA-S cells as APCs. Unless stated otherwise, the data dis- 
cussed below refer to responses measured on day 3  of cul- 
ture.  In all cases,  the  responses were  measured  in  the  ab- 
sence  of exogenous lymphokines; i.e.,  the  responses were 
helper independent. 
CTL  and  Proliferative  Responses  Elicited  by  La-transfected 
RMA-S  Cells.  TAP-2-deficient RMA-S cells cannot load 
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Figure  1.  Phenotype  of T  cells from 2C TCR transgenic mice.  (a) 
CD8, CD44, and 1B2 expression on LN cells from 2C TCtL transgenic 
mice compared with their expression in control B6 mice. Freshly isolated 
LN cells  from B6 and 2C TCtL transgenic mice were double-stained with 
mAbs as described in Materials and Methods; the numbers in parentheses 
refer to the proportion  of CD8 + cells that were CD44 hi. (b) TCR and 
CD8 expression  on purified CD8 § and CD8- 2C T cells.  CD8 + and CD8- 
2C cells were purified as described in Materials and Methods and double- 
stained for expression of CD8 and 1B2. 
intracellular peptides on to class I  molecules: the "empty" 
class I molecules reach the cell surface, especially at lower tem- 
perature,  but  are  unstable  and  rapidly fall apart  (20,  26). 
However, class I expression on RMA-S cells can be stabilized 
and increased to a high level by addition of exogenous pep- 
tides. Expression of L a molecules on  La-transfected RMA-S 
Table 1.  Intrinsic Binding Affinities Involved in 2C-Peptide-L a Interaction, and Stabilization  of L a Expression  on RMA-S.L a 
Cells by Peptides 
Affinity of2C TCR  Stabilization 
Peptides  Sequences  Affinity for L  a  for peptide-L  a  Induction ofL  a at 25~  ofL  a at 37~ 
M- 1  M- 1  MFI  MFI 
p2Ca  LSPFPFDL  4 ￿  106  2 X  106  60  7.0 
QL9  QLSPFPFDL  4  ￿  108  2  ￿  107  63  56.6 
MCMV  YPHFMPTNL  2 ￿  109  NT  38  20.1 
The data on peptide sequences and aflanity measurements are taken from Sykulev et al. (23, 25). Affinity measurement s for 2C TCR binding to sol- 
uble peptide-L  a complexes are based on studies with cell-bound TCR. Experiments ofCorr et al. (24) on soluble TCR yielded a somewhat higher 
aflanity measurement for binding to La-p2Ca complexes, i.e.,  1 ￿  10 -7 M. Induction  and stabilization ofL  d expression by peptides (10 IxM) were 
measured as described in Materials and Methods; the data refer to the MFI ofL  a staining detected with anti-L  a mAb. 
2249  Cai and Sprent cells (R.MA-S.L  d) cultured with p2Ca and QL9 peptides is 
shown in Fig.  2,  a  and b,  and summarized in Table  1.  At 
25~  both peptides  induced strong L d expression.  How- 
ever,  the  concentration  of  peptides  required  to  induce 
maximum L a  expression was  4  logs higher for  p2Ca  than 
for QL9 (Fig. 2  a). Moreover, only the QL9 peptide caused 
stable L a expression at 37~  (Fig.  2  b).  In some of the ex- 
periments  discussed  below,  a  third  peptide,  MCMV,  was 
used as a  control.  This peptide binds strongly to L d (Table 
1) but is nonimmunogenic for 2C ceils. 
R.MA-S  T  lymphoma  cells  lack  B7-1  and  B7-2  and 
show only low levels oflCAM-1  and HSA (Cai, Z., andJ. 
Sprent,  unpublished  data),  lkMA-S  cells  are  thus  poorly 
suited  to  act  as  APCs  for  unprimed T  cells.  To  test  the 
APe  function of RMA-S  cells, CD8 + 2C T  cells were cul- 
tured  with  peptide-pulsed  irradiated  (3,000  cGy)  RMA- 
S.L  d cells in the  absence  of exogenous  lymphokines.  The 
surprising finding was  that  presentation  of p2Ca  or  QL9 
peptide (10 IzM) was strongly immunogenic and led to high 
CTL  responses  (Fig.  2  c,  tested  on day 4  with RMA-S.L d 
targets)  and high proliferative responses (Fig. 2  d, tested on 
day  3).  For  proliferative  responses  (which  are  easier  to 
quantitate  than  CTL  responses),  the  QL9  peptide  was 
clearly  more  immunogenic than  the  p2Ca  peptide,  since 
the  dose  of peptide  required  for  maximal  responses  was 
~100-fold  higher for p2Ca  than for  QL9  (Fig.  2  d).  The 
responses to IKMA-S.L  d ceils were peptide specific, because 
no response occurred to a third peptide, MCMV  (Figs. 2  d 
and 3  c). 
CD8-4-  clonotype-positive (1B2 +) cells are a conspicu- 
ous population in 2C  mice  (15,  27)  (Fig.  1).  In confirma- 
tion of previous findings (15),  the  response  of 2C  cells to 
B10.D2  (L  a) spleen cells in the absence of exogenous lym- 
phokines was very high with  1B2 +  CD8 §  cells but unde- 
tectable with 1B2 + CD8-  cells (Fig. 3 a). Very different re- 
stilts were observed with RMA-S.L  d stimulators (Fig. 3, b-d). 
Here, in the absence of added lymphokines the response to 
the p2Ca peptide (10 txM) was as high with CD8-  2C cells 
as with CD8 +  2C  cells. Paradoxically, with the QL9  pep- 
tide,  responses  were  substantially higher  with  CD8-  cells 
than with CD8 + cells. 
At face value, these findings suggest that, in marked con- 
trast with  normal B10.D2  spleen cells as APCs,  CD8  ex- 
pression  is  not  required  for  the  response  of 2C  cells  to 
P,.MA-S.L  d cells plus exogenous peptides:  CD8  expression 
is  redundant for  the  response  to  p2Ca  and  inhibitory for 
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Figure 2.  Functional properties  of p2Ca  and QL9 
peptides. (a) Induction ofL  d expression on RMA-S.L  d 
cells cultured at 25~  overnight in the presence of dif- 
ferent  concentrations  of p2Ca  or  QL9  peptides; the 
cells were  stained with anti-L  a rnAb and analyzed by 
FACS; the MFI of staining is shown. (b) Stabilization of 
L  a expression as measured by inducing L  d expression 
with peptides overnight at 25~  then raising the tem- 
perature to 37~  for 6 h, followed by staining for L  d 
expression. (c) CTL activity of CD8 + 2C cells elicited 
by RMA-S.L  a stimulators; CD8 + 2C  cells were  cul- 
tured for 4 d with irradiated (3,000 cGy) RMA-S.L  d 
cells plus p2Ca  or QL9  peptides  (10  p.M) and then 
tested for CTL activity on 51Cr-labeled P,  MA-S.L  a tar- 
get cells sensitized with p2Ca  or QL9  peptides or no 
peptide  (Materials and Methods).  (d)  Proliferative re- 
sponses of CD8 +  2C  cells to  peptides  presented  by 
RMA-S.L  d cells; purified LN C1)8 + 2C cells (5 ￿  10  a 
cells per  well)  were  cultured  with  RMA-S.L  a  cells 
(3,000 cOy, 5 X 104 cells  per well) plus the indicated pep- 
tides for 3 d and pulsed with [3H]thyrnidine during the 
last 8 h of culture.  The data shown are the mean re- 
sponse of triplicate cultures. 
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Figure  3.  Proliferative responses of CD8 + vs.  CD8-  2C 
cells to RMA-S.L  d cells plus peptides. Purified populations of 
clonotype-positive (1B2  +) CD8 + and CD8- (CD4-) 2C cells 
prepared from LNs were cultured at 5 ￿  104 cells per well with 
B10.D2 spleen cells (3,000 cGy; 5 ￿  105 cells per well) with- 
out added peptides (a), or with RMA-S.L  a cells (3,000 cGy, 
5 ￿  104 cells per well) supplemented  with the peptides (10 wM) 
indicated (b-d). Cultures were harvested on day 3. 
the response to QL9. Further information on the inhibitory 
effects of CD8 is shown in Fig. 4. With QL9 peptide, it can 
be  seen  that  CD8-  2C  cells  gave  higher  responses  than 
CD8 +  2C  cells  over a  wide  range  of peptide  concentra- 
tions, i.e., from 100 IxM down to 100 pM (Fig. 4, a and b). 
Significantly,  adding  anti-CD8  mAb  to  culture  markedly 
enhanced  the  response  of CD8 +  cells  to  QL9  (Fig.  4  c). 
Thus, in the presence ofanti-CD8 mAb, responses to QL9 
were as high with CD8 + cells as with CD8-  cells.  Interest- 
ingly, the capacity ofanti-CD8 mAb to augment the response 
of CD8 + cells to QL9 also applied to CTLA4Ig (Fig. 4  d). 
This  finding was  unexpected because  RMA-S.L  a cells  are 
B7-.  However,  staining 2C  cells  with  CTLA4Ig revealed 
rapid induction  of B7  expression  after antigen  stimulation 
(data  not  shown),  implying that  the  enhancing  effects  of 
CTLA4Ig reflected binding to B7  on the  responder  cells. 
As controls for these  experiments,  adding anti-L  a mAb to 
culture  inhibited  the  response  of CD8 +  2C  cells  by 50% 
(Fig.  4  d).  Irrelevant mAbs,  e.g.,  anti-CD4,  had  no  effect 
(data not shown). 
The above experiments indicate that helper-independent 
responses  of 2C cells to RMA-S.L  a cells plus QL9 require 
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neither CD8-MHC  interaction nor CD28-B7 interaction. 
In fact,  the  costimulation resulting from these interactions 
is  inhibitory.  To  examine  whether  this  phenomenon  ap- 
plies to conventional APCs, we studied the effects of add- 
ing  p2Ca  and  QL9  peptides  to  normal  B10.D2  spleen 
APCs. 
Proliferative Responses to Spleen Cells and DCs.  In the ab- 
sence of exogenous peptide, the response ofCD8 + 2C cells 
to  normal  B10.D2  spleen  cells  on  day 3  was  reduced  by 
~80%  by CTLA4Ig and  by  >99%  by anti-CD8  or  1B2 
m_Abs  (Table  2).  These  data  with  spleen  stimulators  are 
consistent with the above findings on CD8 + vs. CD8- 2C 
cells  (Fig. 3  a) and reinforce the view that the 2C response 
to normal B10.D2 spleen cells,  i.e., to L d plus small amounts 
of endogenous p2Ca, is heavily dependent upon costimula- 
tion. When the dose ofpeptide presented by B10.D2 spleen 
cells  was increased,  i.e.,  by adding exogenous p2Ca  pep- 
tide, the peak response ofCD8 + 2C cells on day 3 was ele- 
vated  by  approximately  twofold  with  0.1-1.0  IxM  p2Ca 
(data not shown). With higher doses ofp2Ca, the response 
declined  toward  the  level  found  without  added  peptide. 
Significantly, as the dose ofpeptide was raised, the response 250000 
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Figure 4.  Blocking costimulation enhances the day 3 proliferative re- 
sponse of CD8 + 2C cells to QL9 peptide presented by R.MA-S.L  a cells. 
(a and b) Proliferative  responses of varying numbers ofCD8 + vs. CD8  2C 
cells to graded doses ofQL9 peptide added to RMA-S.U  ~  cells. (c) Prolif- 
erative responses ofCD8 + vs CD8- 2C cells (5 ￿  104 cells per well) cul- 
tured  with  QL9-pulsed  P,  MA-S.L  a  cells with  or  without  anti-CD8 
(~xCD8) mAb. (d) Proliferative responses ofCD8 + 2C cells (5 ￿  104 cells 
per well) cultured with QL9  (10  IxM)-pulsed R.MA-S.L  a cells with  or 
without anti-CD8, CTLA4Ig, or anti-L  a mAb. Cultures were harvested  on 
day 3. 
became increasingly resistant to  inhibition with  CTLA4Ig 
or anti-CD8 mAb. In fact, with high doses ofpeptide, these 
reagents augmented the response. 
Similar findings were found with the QL9  peptide, but 
with  two  differences.  First,  the  dose  of QL9  required  to 
augment  the  response  was  -,,10,000-fold  lower  than  for 
p2Ca. Second, in contrast with p2Ca, higher doses of QL9 
(~100 nM) reduced the response to below the level found 
with  normal  B10.D2  spleen  (Table  2).  However,  adding 
CTLA4Ig,  anti-CD8,  or  anti-clonotypic  1B2  mAb  pre- 
vented this reduction and led to very high responses. These 
findings with B10.D2 spleen plus QL9 are thus in close ac- 
cord with the above data on RMA-S.L  d cells. 
The  capacity of high concentrations  of QL9  peptide to 
reduce  the  response  of CD8 +  2C  cells to  B10.D2  spleen 
Table 2.  Proliferative  Response of CD8 + 2C Cells to BIO.D2 
Spleen in the Presence or Absence of QL9 Peptide: Effects of Blocking 
Costimulation 
[3H]Thymidine incorporation (cpm) 
by CD8 + 2C cells cultured with 
B10.D2 
Addition to Culture  spleen 
B10.D2 spleen plus QL9 
peptide (10 ~M) 
Medium alone  198,725  116,348 
CTLA4Ig  39,250  234,707 
Anti-CD8 mAb  206  195,858 
1B2 mAb  140  297,219 
Purified CD8 § 2C cells (2.5 ￿  104 cells per well) were cultured with 
B10.D2 spleen cells (5 ￿  105 cells per well) with or without QL9 pep- 
tide (10 I.LM); CTLA4Ig (1 I.tg/ml of  purified fusion protein), anti-CD8 
mAb (1/1,000,  ascites fluid), or 1B2 mAb (1;1,000, ascites fluid) was 
added at the beginning of culture. Cultures were harvested on day 3. 
stimulators only applied to high doses of spleen cells. Thus, 
with lower doses of spleen cells, adding QL9  peptide had 
the opposite effect and led to enhanced responses (data not 
shown).  These APC  dose-dependent effects of QL9  were 
accentuated when purified B10.D2 DCs were used as a source 
of APCs.  Thus,  adding QL9  (10  I~M)  markedly increased 
the 2C proliferative response to low doses ofB10.D2  DCs 
but profoundly reduced the response to high doses of DCs 
(Fig. 5 a). 
Kinetics of the Response.  The above data indicate that the 
capacity of high doses ofQL9 peptide to inhibit the response 
of  CD8 +  2C  cells  applies  to  three  types  of APC,  i.e., 
P,  MA-S.L  d  cells, B10.D2  spleen  cells,  and  B10.D2  DCs. 
These findings refer to responses measured on day 3 of cul- 
ture  (except for DCs,  where  responses were  measured  on 
day 4).  The  day 3  time point was  chosen  because,  in  the 
absence of exogenous lymphokines, proliferative responses 
of normal (nontransgenic) CD8 + T  cells to class I alloanti- 
gens  presented by  normal  spleen  APCs  generally reach  a 
peak on day 3 and then fall to low levels on day 4  (28). 
As illustrated in Fig. 6 a, these kinetics also applied to the 
proliferative response of CD8 +  2C  cells to B10.D2  spleen 
cells  (without  added  peptides).  However,  when  B10.D2 
spleen cells were supplemented with peptides, the kinetics 
of the  2C  response  changed  considerably.  The  data  dis- 
cussed below refer to proliferative responses; IL-2 produc- 
tion is discussed later. 
With p2Ca peptide,  adding high  (10  DM)  but not low 
(0.1  ~M)  concentrations of this peptide to B10.D2  spleen 
cells prevented the sharp decline in the response on  day 4 
(Fig. 6,  a and b), this effect was transient, and the response 
fell to low levels on  day 5  (Fig. 6  b).  The  data with  QL9 
peptide were different (Fig. 6, a and b). Thus, the inhibition 
of the  response  induced by  0.1-10.0  IxM  QL9  on  day  3 
changed to a marked increase in the response on day 4; the 
response  then  declined  on  day  5,  as  with  p2Ca  peptide. 
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Figure 5.  Profiferative responses and IL-2 production  by 
CD8 + 2C cells responding  to B10.D2  DCs supplemented 
with QL9  peptide.  CD8 +  2C  cells  (2.5  ￿  104  cells  per 
well) were cultured with graded doses of DCs in the pres- 
ence or absence of QL9 peptide  (10 IxM). Proliferative re- 
sponses were measured on day 4  (a), and IL-2 production 
was measured on day 2  (48 h)  (b); IL-2 was measured by 
adding culture supematant to CTLL-2 indicator cells and, 
24 h later, pulsing  the indicator  cells with [3H]thymidine 
for 16 h (Materials and Methods). 
(Note  that  in  Fig.  6  b,  the  response  to  the  lower  dose  of 
p2Ca  peptide  was  essentially  the  same  as  to  spleen  cells 
without added peptide; for simphcity, these control data are 
not shown.) 
The  capacity  of QL9  peptide  to  augment  the  late  re- 
sponse  of 2C  cells  was  more  pronounced with DCs  than 
with APCs.  Without peptide,  the 2C  response to B10.D2 
DCs  reached a peak  on day 3  (as with spleen APCs)  and 
then  declined  to baseline levels  by  day 5  (Fig.  7).  When 
supplemented with a high dose of QL9 peptide  (10 txM), 
however,  the  response  to  DCs  was  markedly  reduced  on 
day  3  and  then  increased  to  very  high levels  on  day 5  be- 
fore declining  on day 6.  Titration  experiments  (not shown) 
indicated  that  generation  of high  responses  on  day  5  re- 
quired both a high dose ofpeptide and a high dose of APCs. 
The  above  data  indicate  that  the  inhibition  of prolifera- 
tion induced by a high dose ofQL9 peptide is transient and 
is  followed  by  heightened  responses  later  in  culture.  IL-2 
production  in the cultures  is discussed below. 
IL-2 Production.  In accordance  with previous findings (15), 
in the absence  of added peptide,  IL-2 production  elicited by 
normal  B10.D2  spleen  ceils  or  DCs  as APCs  was  low  but 
detectable early in culture (days  1 and 2)  and fell to back- 
ground levels by day 3  (Fig.  8).  As shown  in Figs.  5-8,  the 
capacity  of QL9  peptide  to  inhibit  the  early  proliferative 
response  of CD8 +  2C  cells  was  not  associated  with  a  re- 
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Figure  7.  Kinetics of proliferation and IL-2 production by CD8 + 2C 
cells responding to QL9 peptide presented by B10.D2 DCs. Doses of 2.5 ￿ 
10  4 CD8  + 2C cells were cultured with 7 ￿  10  4 B10.D2 DCs in the presence 
or absence ofQL9 peptide (10 bLM). Proliferative responses (a) were mea- 
sured on days 2-6, whereas IL-2 production (b) was measured on days 1-5. 
duction in IL-2 production.  In fact, the inhibition  of pro- 
liferation induced by QL9 was invariably associated with a 
substantial  increase  in  IL-2  production,  both  with  DCs 
(Figs.  5 and 7) and spleen cells (Figs.  6 and 8) as APCs. Ti- 
tration experiments showed that elevation of IL-2 produc- 
tion was both directly proportional to the  dose of peptide 
and dose of APC used, and also considerably stronger with 
QL9 than p2Ca, especially late in culture (data not shown). 
In the case ofQL9 peptide,  IL-2 production remained high 
until  day 3-4  of culture  and  then  declined  toward  back- 
ground levels on day 4-5 (Figs.  6 and 7). The late prolifer- 
ative response elicited by QL9 thus correlated with strong 
and sustained production of IL-2. In general, the decline in 
the proliferative response to QL9 was preceded by a fall in 
IL-2 production  1 d earlier (Figs.  6 and 7). 
The influence  of costimulation on proliferation vs.  IL-2 
production is illustrated in Fig. 8, with B10.D2 spleen cells 
as APCs. As discussed earlier,  adding a high dose of QL9 pep- 
tide  (10  ~,M)  inhibited  the proliferative response on day 3 
but enhanced the response on day 4, the enhanced prolifer- 
ative response on day 4 correlated with enhanced IL-2 pro- 
duction on day 2 and day 3. Significantly, blocking costim- 
ulation with anti-CD8 mAb or CTLA4Ig reduced the high 
proliferative  response  induced by QL9  (10  IxM)  on day 4 
and  caused  a  parallel  reduction  in  IL-2 production  1  day 
earlier, i.e., on day 3. Thus, in contrast with the early (day 3) 
proliferative response, the late (day 4) proliferative response 
to QL9 required costimulation: blocking costimulation re- 
duced IL-2 production earlier in culture  (day 3)  and thereby 
abbreviated the proliferative response. Similar findings were 
found with RMA-S.L  d cells as APCs (data not shown). 
The main conclusion from these experiments is that co- 
stimulation is essential for the late response of CD8 + cells. 
Costimulation boosts IL-2 production and thus allows the 
ceils  to proliferate for a prolonged period. 
Discussion 
The main goal of this paper was to examine the primary 
response  of naive  CD8 §  T  cells  under various  conditions 
and determine whether the avidity of T  ceil-APC interac- 
tion affects the requirement for costimulation. As discussed 
earlier,  the  2C  system  is  ideally  suited  for addressing  this 
question because the binding affinities involved in  TCR- 
peptide-MHC interaction are well characterized. With this 
system,  we  show  here  that  altering  the  avidity of T  ceil- 
APC  interaction  induces  surprisingly  complex  changes in 
the kinetics of the primary responses. 
Primary  responses  of CD8 +  cells  to  class  I  ailoantigens 
are  often undetectable  unless  the  cells  receive  help  in  the 
form of exogenous cytokines. These helper-dependent  re- 
sponses of CD8 +  cells  reflect low-avidity T  ceil-APC  in- 
teractions  (15,  29)  and  are  epitomized by the  response  of 
CD8 +  2C  cells  to  the  weak  K bin11 alloantigen  (15).  With 
stronger ailoantigens, the requirement for help does not ap- 
ply,  and CTL and proliferative  responses  occur in the  ab- 
sence  of exogenous  lymphocytes.  These  helper-indepen- 
dent responses  can be spectacularly  high but  are  generally 
of short duration  and easily inhibited with anti-CD8  mAb 
or CTLA4Ig (9,  28).  These  features apply to the response 
of CD8 §  2C  cells  to  normal  B10.D2  APCs,  a  situation 
where the cells  react to ailo- L d molecules complexed with 
small amounts of endogenous p2Ca peptide. We show here 
that exposure to QL9, a variant ofp2Ca with very high af- 
finity for both L ~ and the 2C TCR, caused radical changes 
in the response of CD8 + 2C cells.  Adding high concentra- 
tions  of QL9 peptide  to  tLMA-S.L  d cells,  B10.D2  spleen 
cells,  or B10.D2  DCs  as  APCs led paradoxically  to  a  re- 
duced proliferative response on day 3. However, responses 
on day 4-5 were markedly elevated.  This  alteration  in  ki- 
netics induced by QL9 peptide required costimulation. Thus, 
preventing costimulation improved the low day 3 prolifer- 
ative response but reduced the high day 4-5 response. The 
role of costimulation during the early and late phases of the 
proliferative response is discussed below. 
Reduction of the Response on Day 3.  Since  peptide-induced 
inhibition of the CD8 + 2C proliferative response on day 3 
was unique  to the high affinity QL9 peptide  and required 
large doses of APCs, the inhibition could be a consequence 
of very high avidity T  ceil-APC interaction leading to ex- 
cessive T  cell triggering. The observation that blocking co- 
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stimulation  with  anti-CD8  mAb  or  CTLA4Ig overcame 
the  inhibition,  presumably by reducing the level of T  cell 
triggering,  is consistent with this interpretation.  However, 
explaining the data in terms of excessive T  cell  triggering is 
clearly complicated by the  sharp  increase  in the  prolifera- 
tive response after day 3.  It is also notable that the inhibi- 
tion on day 3 applied only to proliferation and not to IL-2 
production.  Indeed, with high doses of QL9, proliferation 
and IL-2 production on day 3 seemed to be inversely cor- 
related; thus, blocking costimulation improved the prolifer- 
ative response but reduced IL-2 production. 
The early inhibition  of proliferation could be the coun- 
terpart  of antigen-induced suppression  reported for CD4 + 
cells in vitro  (30,  31).  In favor of this idea,  suppression  of 
CD4 + cells  by high doses of antigen is associated with re- 
duced  proliferative  responses  but  high  IL-2  production. 
However,  the  inhibition  of proliferation  seen  in  antigen- 
induced suppression is apparent at both early and late stages 
of culture  and  is  associated  with  cell  death  by  apoptosis 
(31).  This clearly contrasts with the present data on CD8 + 
cells,  where the inhibition of proliferation was transient and 
was followed by very high proliferative responses later in cul- 
ture.  Moreover,  examining the  cultures  on day 3  showed 
no evidence that the inhibition  of proliferation was associ- 
ated with  an increase  in cell death  (Cai,  Z.  and J.  Sprent, 
unpublished  data).  In  considering  other  possibilities,  we 
2255  Cai and Sprent have found that QL9 peptide induces marked TCR down- 
regulation early in culture  (Cai,  Z., and J. Sprent, unpub- 
lished data). However, the possibility that TCR downreg- 
ulation  accounted  for  the  inhibition  of  proliferation  is 
unlikely for two  reasons.  First,  TCR  downregulation  did 
not impede high IL-2 production. Second, in contrast with 
the inhibition of proliferation, we have found no evidence 
that costimulation is required for TCR downregulation. 
The precise  cause  of the  inhibition  of proliferation in- 
duced by QL9 peptide remains unclear.  Our working hy- 
pothesis is that this phenomenon is a reflection of  very strong 
T  cell signaling leading to the transient production  of cell 
cycle inhibitors (32). In this respect, many of the T  cells har- 
vested at the stage when the proliferative response is inhib- 
ited are locked in  G 1 (unpublished data).  The level of cell 
cycle inhibitors in these cells is under investigation. 
At face value,  the  capacity of CTLA4Ig to prevent the 
inhibition of day 3 proliferative responses is consistent with 
the evidence that B7 interaction with T  cell CTLA4 leads 
to negative signaling (33,  34). The problem with this inter- 
pretation is that the augmentation of the day 3 response by 
CTLA4Ig also applied to anti-CD8 mAb. Hence, the inhi- 
bition  of proliferation is more likely to be a reflection of 
high avidity T  cell-APC interaction than selective negative 
signaling mediated through CTLA4. 
Elevation of the Response on Day 4-5.  As  discussed  earlier, 
typical helper-independent  proliferative responses  of nor- 
mal CD8 +  T  cells  are usually of brief duration  unless  the 
cultures  are supplemented with  exogenous  IL-2. The  ca- 
pacity of QL9 peptide to elicit high proliferative responses 
late in culture was thus unexpected. 
The kinetics of the late proliferative response to QL9 cor- 
related closely with levels of IL-2 in the cukures. Thus, IL-2 
production  was low and brief in the  absence of QL9 but 
high and prolonged in the presence of QL9. In each situa- 
tion,  the decline in IL-2 production to baseline levels was 
followed 1 d later by an abrupt decline in the proliferative 
response.  The  capacity  of QL9  peptide  to  induce  pro- 
longed  proliferation  can thus  be attributed  simply to  sus- 
tained  production  of IL-2,  presumably  as  a  reflection  of 
strong T  cell stimulation. This scenario predicts that reduc- 
ing the level of T  cell stimulation would impair IL-2 pro- 
duction and abbreviate the proliferative response.  The ef- 
fects of blocking costimulation bear out this prediction. 
Concluding Comments.  A  corollary of the avidity model 
of T  cell-APC  interaction  (8)  is that second signals  deliv- 
ered  via  costimulatory  molecules  become  less  important 
when the avidity of interaction between T  cells and APCs 
is very high. The findings that B7- RMA-S cells were sur- 
prisingly effective APCs for 2C cells and that CTLA41g im- 
proved rather than reduced the early proliferative response 
to QL9 are consistent with this prediction. We caution, how- 
ever, that RMA-S  cells  do express low levels of ICAM-1 
and  HSA.  Thus,  costimulation  through  these  molecules 
could substitute  for CD28-B7  interaction.  Moreover,  the 
possibility that  RMA-S  cells  express yet other  costimula- 
tory molecules cannot be discounted.  Despite this reserva- 
tion, the data do indicate that costimulation via CD8-class 
I and CD28-B7 interactions is much less important for re- 
sponses to strong antigens  (B10.D2  APCs plus QL9)  than 
to weak antigens (B10.D2 APCs alone). 
Despite  these  findings  on  early  proliferative  responses, 
costimulation played a  crucial role in prolonging the  pri- 
mary response, presumably through intense  production  of 
IL-2.  Thus,  in  the  absence  of costimulation,  the  primary 
response to strong antigens, though initially intense, was of 
brief duration,  reflecting rapid consumption  of IL-2. The 
capacity of costimulation  to  prolong  the  intensity  of the 
primary response has not been reported previously and adds 
a new dimension to the importance of costimulation in the 
immune response. 
We thank Ms. Barbara Marchand for typing the manuscript, Dr. Dennis Loh for providing us with 2C mice, 
Dr. Herman Eisen for sending us RMA-S and 1B2 hybridoma lines, and Dr. Anders Brunmark for provid- 
ing us with peptides. We also thank Drs. Hidehiro  Kishimoto, Jonathan  Kaye, Anne O'Rourke, Charles 
Surh, and David Tough for their comments on the paper. 
This work was supported by grants CA-38355, CA-25803, AI-32068, and AI-21487 from the United States 
Public Health Service. This is publication 9534-IMM from The Scripps Research Institute. 
Address correspondence to Jonathan Sprent, M.D., Ph.D., Department of Immunology, IMM4, The Scripps 
Research Institute, 10666 N. Torrey Pines Rd., La Jolla, CA 92037. 
Received  for publication 19 September 1995 and in revised  form  15 February 1996. 
References 
1.  Germain,  R.N.  1993. Antigen  processing and presentation. 
In  Fundamental  Immunology.  W.E.  Paul,  editor.  Raven 
Press, New York. 629-676. 
2. Janeway,  C.A.  1992. The T  cell receptor as a multi-compo- 
nent signalling machine:  CD4/CD8  coreceptors  and CD45 
in T cell activation. Annu. Rev. Immunol. 10:645-674. 
3.  Miceh, M.C., andJ.R. Parnes. 1993. Role of CD4 and CD8 in 
T cell activation and differentiation. Adv. Immunol. 53:59-122. 
4.  Schwartz, R.H.  1992. Costimulation  of T  lymphocytes:  the 
role  of CD28, CTLA-4, and B7/BB1  in interleukin-2  pro- 
2256  CD8 and B7 Can Inhibit T Cell Function duction and immunotherapy. Cell. 71:1065-1068. 
5. June,  C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thomp- 
son. 1994. The B7 and CD28 receptor families. Immunol.  To- 
day. 15:321-331. 
6.  Linsley, P.S., andJ.A. Ledbetter. 1993. The role of the CD28 
receptor during T  cell responses to antigen. Annu.  Rev.  Im- 
munol.  11:191-212. 
7. Janeway, C.A., and K. Bottomly. 1994.  Signals and signs for 
lymphocyte responses. Cell. 76:275-285. 
8.  Sprent, J., E.K. Gao, and S.lL. Webb. 1990.  T  cell reactivity 
to  MHC  molecules:  immunity  versus  tolerance.  Science 
(Wash.  DC). 248:1357-1363. 
9.  Harding, F.A., and J.P. Allison. 1993.  CD28-B7 interactions 
allow the induction ofCD8 + cytotoxic T lymphocytes in the 
absence of exogenous help./. Exp. Meal. 177:1791-1796. 
10. Shahinian, A., K. Pfeffer,  K.P. Lee, T.M. Kundig, K. Kishi- 
hara, A. Wakeham, K. Kawai, P.S. Ohashi, C.B. Thompson, 
and  T.W.  Mak.  1993.  Differential T  cell costimulatory re- 
quirements  in  CD28-deficient  mice.  Science (Wash.  DC). 
261:609-612. 
11. Green, J.M.,  P.J.  Noel,  A.I.  Sperling, T.L.  Walunas,  G.S. 
Gray, J.A. Bluestone, and C.B. Thompson. 1994. Absence of 
B7-dependent responses in CD28-deficient mice. Immunity. 
1:501-508. 
12. Maryanski, J.L.,  P.  Pala, J.-C.  Cerottini,  and  H.lL.  Mac- 
Donald. 1988. Antigen recognition by H-2-restricted cytolytic 
T lymphocytes: inhibition ofcytolysis  by anti-CD8 monoclonal 
antibodies depends upon both concentration and primary se- 
quence ofpeptide antigen. Eur.J. Immunol.  18:1863-1866. 
13. Auphan, N., J. Cumow, A. Guimezanes, C. Langlet, B. Ma- 
lissen,  A.  Mellor,  and  A.-M.  Schmitt-Verhulst.  1994.  The 
degree of CD8  dependence of cytolytic T  cell precursors is 
determined by the nature of the T  cell receptor (TClL) and 
influences negative selection in TClL-transgenic mice. Eur. J. 
Immunol.  24:1572-1577. 
14. Sha, W.C., C.A. Nelson, lL.D. Newberry, D.M. Kranz, J.H. 
lLussell, and D.Y. Loh. 1988.  Selective expression of an anti- 
gen receptor on  CD8-bearing T  lymphocytes in transgenic 
mice. Nature (Lond.). 335:271-274. 
15. Cai, Z., andJ. Sprenc 1994. lLesting and activated T cells dis- 
play different requirements for CD8  molecules. J.  Exp.  Med. 
179:2005-2015. 
16. Udaka, K., T.J. Tsomides, and H.N. Eisen. 1992. A naturally 
occurring peptide recognized by alloreactive CD8 + cytotoxic 
T  lymphocytes in  association with  a  class I  MHC  protein. 
Cell. 69:989-998. 
17. Kranz, D.M.,  S. Tonegawa, and H.N.  Eisen.  1984.  Attach- 
ment of an anti-receptor antibody to non-target cells renders 
them susceptible to lysis by a clone of cytotoxic T  lympho- 
cytes. Proc. Natl. Acad. Sci. USA. 81:7922-7926. 
18. Linsley, P.S., J.L. Greene, P. Tan, J. Bradshaw, J.A. Ledbet- 
ter,  C.  Anasetti, and N.K.  Damle.  1992.  Coexpression and 
functional cooperation of CTLA-4 and CD28 on activated T 
lymphocytes.J. Exp. Med.  176:1595-1604. 
19. Sprent, J.,  and M.  Schaefer.  1989.  Antigen-presenting cells 
for  Lyt-2  +  cells.  II.  Primary  mixed-lymphocyte  reactions 
stimulated by Ia  + dendritic cells and Ia- peritoneal exudate 
cells. Int.  ImmunoI.  1:517-525. 
20. Ljunggren, H.-G., NJ.  Stare,  C.  Ohlen, J.J.  Neetjes, P.  Ho- 
glund,  M.  Heemels,  J.  Bastin,  T.N.M.  Schumacher,  A. 
Townsend, K. Karre, and H.L. Ploegh. 1990. Empty MHC class 
I molecules come out in the cold. Nature (Lond.). 346:476-480. 
21. Sha, W.C., C.A. Nelson, R.D. Newberry, J.K. Pullen, L.lL. 
Pease, J.H. lLussell, and D.Y. Loh. 1990. Positive selection of 
transgenic receptor-bearing thymocytes by K  b antigen is al- 
tered  by  K  b mutations  that  involve peptide binding.  Proc. 
Natl. Acad. Sci. USA. 87:6186-6190. 
22. Udaka, K., TJ. Tsomides, P. Walden, N. Fukusen, and H.N. 
Eisen.  1993.  A  ubiquitous protein is the source of naturally 
occurring peptides  that  are  recognized by  a  CD8 +  T-cell 
clone. Proc. Natl. Acad. Sci. USA. 90:11272-11276. 
23. Sykulev, Y.,  A.  Brunmark,  M. Jackson,  lL.J.  Cohen,  P.A. 
Peterson, and H.N. Eisen. 1994. Kinetics and affinity of reac- 
tions between an antigen-specific T  cell receptor and pep- 
tide-MHC complexes. Immunity.  1:15-22. 
24. Corr, M., A.E. Slanetz, L.F. Boyd, M.T. Jelonek, S. Khilko, 
B.K.  Al-lLamadi, Y.  Sang Kim, S.E. Maher, A.L.M. Both- 
well, and D.H. Margulies. 1994. T cell receptor-MHC class I 
peptide interactions: affinity, kinetics, and specificity. Science 
(Wash. DC). 265:946-949. 
25. Sykulev, Y., A. Brunmark, T.J.  Tsomides, S. Kageyama, M. 
Jackson, P.A. Peterson, and H.N. Eisen. 1994.  High-affinity 
reactions between antigen-specific T-cell receptors and pep- 
tides associated with  allogeneic and syngeneic major histo- 
compatibility complex class I proteins. Proc. Natl. Acad.  Sci. 
USA. 91:11487-11491. 
26. Yang,  Y.,  K.  Fruh, J.  Chambers, J.B.  Waters,  L.  Wu,  T. 
Spies,  and  P.A.  Peterson.  1992.  Major  histocompatibility 
complex (MHC)-encoded HAM2 is necessary for antigenic 
peptide loading onto class I MHC molecules. J.  Biol. Chem. 
267:11669-11672. 
27. Russell, J.H.,  P.  Meleedy-Rey, D.E.  McCulley, W.C.  Sha, 
C.A. Nelson, and D.Y. Loh.  1990.  Evidence for CD8-inde- 
pendent  T  cell maturation in  transgenic  mice. d.  Immunol. 
144:3318-3325. 
28.  Sprent, J.,  M.  Schaefer,  D.  Lo,  and  1K.  Korngold.  1986. 
Functions of purified L3T4 + and Lyt-2  + cells in vitro and in 
vivo. Immunol. Rev. 91:195-218. 
29. Heath, W.lL., L. Kjer-Nielsen, and M.W. Hoffmann.  1993. 
Avidity for antigen can influence the helper dependence of 
CD8 + T lymphocytes.,/. Immunol.  151:5993-6001. 
30. Suzuki, G., Y. Kawase, S. Koyasu, I. Yahara, Y. Kobayashi, 
and  lL.H.  Schwartz.  1988.  Antigen-induced suppression of 
the T proliferative response ofT cell clones@ Immunol.  140: 
1359-1365. 
31. Critchfield, J.M.,  M.K.  lLacke, J.C.  Zuniga-Pflucker,  B. 
Cannella, C.S. lKaine, J. Goverman, and MJ. Lenardo. 1994. 
T  cell deletion in high antigen dose therapy of autoimmune 
encephalomyelitis. Science (Wash.  DC). 263:1139-1143. 
32.  Nourse, J.,  E.  Firpo, W.M.  Flanagan, S.  Coats, K.  Polyak, 
M.H.  Lee, J.  Massagu4,  G.lL.  Crabtree,  and J.M.  lLoberts. 
1994.  Interleukin-2-mediated elimination of the p27  Kip1 cy- 
clin-dependent kinase inhibitor prevented by rapamycin. Na- 
ture (Lond.). 372:570-573. 
33. Waterhouse, P., J.M. Penninger, E. Timms, A. Wakeham, A. 
Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T.W. 
Mak. 1995.  Lymphoproliferative disorders with early lethality 
in mice deficient in CTLA-4. Sdence (Wash. DC). 270:985-988. 
34. Tivol, E.A., F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. 
Bluestone, and A.H. Sharpe. 1995.  Loss of CTLA-4 leads to 
massive lymphoproliferation  and fatal multiorgan tissue destruc- 
tion, revealing a critical negative regulatory role of CTLA-4. 
Immunity.  3:541-547. 
2257  Cai and Sprent 